The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Biomarkers and surrogate endpoints in clinical trials
Open accessAbstract
One of the most important considerations in designing clinical trials is the choice of outcome measures. These outcome measures could be clinically meaningful endpoints that are direct measures of how patients feel, function, and survive. Alternatively, indirect measures, such as biomarkers that include physical signs of disease, laboratory measures, and radiological tests, often are considered as replacement endpoints or ‘surrogates’ for clinically meaningful endpoints. We discuss the definitions of clinically meaningful endpoints and surrogate endpoints, and provide examples from recent clinical trials. We provide insight into why indirect measures such as biomarkers may fail to provide reliable evidence about the benefit‐to‐risk profile of interventions. We also discuss the nature of evidence that is important in assessing whether treatment effects on a biomarker reliably predict effects on a clinically meaningful endpoint, and provide insights into why this reliability is specific to the context of use of the biomarker. Copyright © 2012 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210629 · Cited by 3,300
Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,253
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Self-citationIntensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Kalantar-Zadeh, K. (2017) · American Journal of Nephrology · doi:10.1159/000455387 · Cited by 1,148
Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., & Ring, L. (2011) · Value in Health · doi:10.1016/j.jval.2011.06.013 · Cited by 1,135
Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., & Ring, L. (2011) · Value in Health · doi:10.1016/j.jval.2011.06.014 · Cited by 1,095
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Weir, M. (1990) · Cardiopulmonary Physical Therapy Journal · doi:10.1097/01823246-199001020-00009 · Cited by 1,058
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease
The International Chronic Granulomatous Disease Cooperative Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199102213240801 · Cited by 830
Gustafsson, L., Hallander, H. O., Olin, P., Reizenstein, E., & Storsaeter, J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602083340602 · Cited by 737
A Comparison of Reteplase with Alteplase for Acute Myocardial Infarction
(1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371603 · Cited by 676
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
How the Target Hemoglobin of Renal Anemia Should Be?
Mimura, I., Tanaka, T., & Nangaku, M. (2015) · Nephron · doi:10.1159/000440849 · Cited by 416
Francis, C. W., Berkowitz, S. D., Comp, P. C., Lieberman, J. R., Ginsberg, J. S., Paiement, G., Peters, G. R., Roth, A. W., McElhattan, J., & Colwell, C. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035162 · Cited by 321
Study of Heart and Renal Protection (SHARP)
Baigent, C., & Landry, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.4.x · Cited by 320
Cannon, C. P., Giugliano, R. P., Blazing, M. A., Harrington, R. A., Peterson, J. L., Sisk, C. M., Strony, J., Musliner, T. A., McCabe, C. H., Veltri, E., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.07.023 · Cited by 299
Smalling, R. W., Bode, C., Kalbfleisch, J., Sen, S., Limbourg, P., Forycki, F., Habib, G., Feldman, R., Hohnloser, S., & Seals, A. (1995) · Circulation · doi:10.1161/01.cir.91.11.2725 · Cited by 287
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
Reboldi, G., Gentile, G., Angeli, F., Ambrosio, G., Mancia, G., & Verdecchia, P. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283469976 · Cited by 275
Surrogate Endpoints And FDA’s Accelerated Approval Process
Fleming, T. R. (2005) · Health Affairs · doi:10.1377/hlthaff.24.1.67 · Cited by 249
Self-citationClinical measurement in drug evaluation
Ellenberg, S. S. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)82386-5 · Cited by 146
ColwellJr., C. W. (2005) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.d.02184 · Cited by 74
Cited by
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137
Risk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Biomarkers of aging for the identification and evaluation of longevity interventions
Moqri, M., Herzog, C., Poganik, J. R., Justice, J., Belsky, D. W., Higgins-Chen, A., Moskalev, A., Fuellen, G., Cohen, A. A., Bautmans, I., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.003 · Cited by 736
Metadata
- Authors
- Fleming, T. R., & Powers, J. H.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 2012-06-18
- Volume
- 31
- Issue
- 25
- Pages
- 2973-2984
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W2028590696
- Cited by
- 544
- References
- 35
- FWCI
- 26.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.